Experimental cell therapy takes on Hard-to-Treat cancers
NCT ID NCT04898543
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-stage study is testing a new treatment for people with advanced solid tumors that have spread. The treatment uses a patient's own immune cells, called M-CENK, which are collected, processed, and given back along with a booster drug called N-803. The main goal is to see if the approach is safe, with 50 participants split into two groups based on how many prior treatments they have had.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M-CENK (a type of immune cell) and N-803 (a drug that boosts immune cells)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety, not effectiveness. The treatment may not shrink tumors or improve survival, and there are risks of side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.